Cyclacel Pharmaceuticals Inc  

(Public, NASDAQ:CYCC)   Watch this stock  
Find more results for CYCC
3.48
+0.20 (6.10%)
Apr 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.23 - 3.58
52 week 2.75 - 5.50
Open 3.28
Vol / Avg. 276,507.00/178,475.00
Mkt cap 78.91M
P/E     -
Div/yield     -
EPS -1.16
Shares 22.68M
Beta 1.60
Inst. own 10%
Feb 10, 2014
Cyclacel Pharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1195.32% -941.88%
Operating margin -1329.10% -1658.12%
EBITD margin - -1651.66%
Return on average assets -39.00% -37.21%
Return on average equity -50.97% -102.70%
Employees 17 -
CDP Score - -

Address

SUITE 1500, 200 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
United States - Map
+1-908-5177330 (Phone)
+1-866-2713466 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.

Officers and directors

David C. U'Prichard Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Spiro George Rombotis President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Independent Vice Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Paul McBarron Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Judy H. Chiao M.D. Vice President - Clinical Development and Regulatory Affairs
Age: 53
Bio & Compensation  - Reuters
Nicholas G. Bacopoulos Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
John Michael Middlecott Banham Independent Director
Age: 73
Bio & Compensation  - Reuters
Gregory T. Hradsky Independent Director
Age: 51
Bio & Compensation  - Reuters
Lloyd M. Sems Independent Director
Age: 42
Bio & Compensation  - Reuters